Goldman Sachs’ portfolio strategy research team has identified China healthcare stocks — especially pharmaceutical names — as a strategic “post‑AI” trade after AI‑related gains concentrated returns in hardware and semiconductor companies, according to a Sept. 7 research note cited by CNBC.
What Goldman said and which stocks it highlighted
Goldman’s analysts found that nearly half of MSCI China constituents beat earnings estimates in the second quarter. The bank reports Chinese earnings it tracks grew 24% year‑on‑year in Q2, the fastest quarterly pace in five years and a sharp acceleration from 6% in Q1. Much of the earlier upside was driven by AI‑related companies, the research team said.
Seeking areas outside an increasingly crowded AI hardware ecosystem, Goldman screened its buy‑rated China coverage for companies with expected earnings growth of more than 15% annually through 2027 and a median 7% upward revision to earnings per share estimates over the prior month. The screen favoured names where Goldman’s own earnings forecasts exceeded consensus.
From that process, healthcare — particularly pharmaceuticals — accounted for one‑third of the 12 final names that made Goldman’s list. CNBC reported the four pharmaceutical companies explicitly mentioned by Goldman as examples:
- Innovent Biologics (Suzhou‑based): Goldman projects earnings that are expected to more than double in the year ahead, and the bank’s expected growth is 54 percentage points higher than consensus. The company is described as claiming a pipeline including cancer and metabolic disease drugs.
- BeOne Medicines (Shanghai‑listed; also listed on Nasdaq and Hong Kong): Earnings are also expected to more than double in the year ahead; the company develops cancer treatments.
- CSPC (Hong Kong‑listed): Goldman expects earnings to grow by 26%; the firm’s major businesses include nervous system and cardiovascular drugs.
- Hansoh Pharma (Hong Kong‑listed): Earnings are forecast to grow by 15%; products cover metabolic and cancer treatments.
Goldman’s analysts note that if these four companies achieve the forecasted growth, they would outpace Goldman’s more conservative view of MSCI China overall: the bank expects MSCI China earnings to grow by 8% this year versus a 17% consensus forecast, per CNBC.
How Goldman frames the ‘post‑AI’ trade
The bank says investor attention has expanded beyond hardware and semiconductors into downstream and application sectors — for example, data‑center operators, AI models, autos and healthcare — as AI becomes more crowded. Goldman’s screen deliberately looked for companies whose earnings could be revised higher soon, judging by recent analyst upgrades and internal estimates above consensus.
Context and implications for investors
Goldman’s move reflects two linked dynamics reported by CNBC: (1) a concentrated run in AI‑related names that lifted aggregate earnings growth in the Chinese market, and (2) investor interest in finding growth outside the highly bid AI hardware ecosystem.
For investors, Goldman’s approach is explicit and rule‑based: select buy‑rated China coverage, require expected earnings growth >15% annually through 2027, and recent upward revisions to EPS estimates. That filtering favoured pharma because several companies showed both high near‑term growth expectations and recent analyst estimate upgrades.
Evidence comparison and practical takeaways
Comparing claims across the reporting:
- Goldman’s reported aggregate Q2 earnings pace for tracked Chinese stocks: 24% year‑on‑year growth, up from 6% in Q1 (CNBC).
- Goldman’s MSCI China earnings forecast for the year: 8%, which CNBC notes is below the market consensus of 17%.
- Specific company growth expectations as reported by Goldman: Innovent and BeOne are expected to “more than double” earnings in the year ahead; CSPC +26%; Hansoh Pharma +15% (CNBC).
Actionable checklist for investors who want to evaluate Goldman’s suggested trade further (based on how Goldman constructed its screen):
- Confirm whether a candidate stock is within Goldman’s buy‑rated China coverage and note Goldman’s published estimates vs consensus.
- Check expected earnings growth through 2027: is it >15% annually per the analyst report?
- Review recent EPS revisions: has the median EPS estimate moved up by roughly 7% over the past month?
- Compare Goldman’s estimate to consensus — the screen favoured names where Goldman’s forecast is higher than consensus.
- Assess company fundamentals specific to pharma: pipeline stage, regulatory readouts and revenue visibility from marketed products.
- Factor in market‑level assumptions: Goldman’s MSCI China earnings growth view (8% for the year) is more conservative than consensus (17%), which affects relative return expectations.
Unresolved points and limitations
CNBC’s report relays Goldman’s analysis but does not publish the full list of 12 companies, the detailed screening table, or Goldman’s underlying model inputs. The exact drivers behind Goldman’s outsized forecasts for Innovent and BeOne compared with consensus are not detailed in the CNBC summary. CNBC also attributes portions of the story to Michael Bloom for contribution.
Why this matters
Goldman’s note shows a shift in thematic investor search beyond headline AI hardware winners to sectors where AI can be applied — notably healthcare diagnostics, drug development and software — and where some Chinese pharmaceutical names appear to have projected earnings momentum. For traders and longer‑term investors, Goldman’s screening checklist above provides a repeatable way to assess whether other China healthcare names may fit the same criteria.
“As AI‑related stocks become increasingly crowded and concentrated, many investors are looking for additional growth opportunities beyond the AI Hard Tech ecosystem,” Goldman Sachs’ portfolio strategy research team said, as reported by CNBC.